Shanghai Rightongene Biotechnology Management

Management criteria checks 3/4

Shanghai Rightongene Biotechnology's CEO is Hui Xiong, appointed in Dec 2018, has a tenure of 5.42 years. directly owns 18.22% of the company’s shares, worth CN¥251.36M. The average tenure of the management team and the board of directors is 4.8 years and 5.4 years respectively.

Key information

Hui Xiong

Chief executive officer

CN¥608.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	5.4yrs
CEO ownership	18.2%
Management average tenure	4.8yrs
Board average tenure	5.4yrs

Recent management updates

Recent updates

Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Apr 23

CEO

Hui Xiong (51 yo)

5.4yrs

Tenure

CN¥608,200

Compensation

Ms. Hui Xiong is Chairman and General Manager at Shanghai Rightongene Biotechnology Co., Ltd. since December 19, 2018.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hui Xiong	Chairman & GM of Core Technology Personnel	5.4yrs	CN¥608.20k	18.22% CN¥ 251.4m
Yan Li	Secretary of the Board of Directors & CFO	4.2yrs	CN¥1.75m	0.013% CN¥ 177.8k
Jun Xiong	Deputy GM & Director	5.4yrs	CN¥609.20k	no data
Chengli Zhang	Deputy General Manager	4.2yrs	CN¥481.10k	0.011% CN¥ 148.2k
Liqun Xie	Deputy General Manager	no data	CN¥676.40k	0.011% CN¥ 148.2k
Junyan He	Deputy General Manager	no data	no data	0.032% CN¥ 434.7k

4.8yrs

Average Tenure

51yo

Average Age

Experienced Management: 688217's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hui Xiong	Chairman & GM of Core Technology Personnel	5.4yrs	CN¥608.20k	18.22% CN¥ 251.4m
Jun Xiong	Deputy GM & Director	5.4yrs	CN¥609.20k	no data
Guiying Zhao	Independent Director	5.4yrs	CN¥80.00k	no data
Shangxian Gao	Director	5.4yrs	no data	no data
Xuewei Yuan	Independent Director	5.4yrs	CN¥80.00k	no data
Weijian Xu	Independent Director	5.4yrs	CN¥80.00k	no data
Yunhang Li	Chairman of the Supervisory Board	5.3yrs	no data	no data
Jie Shen	Member of the Supervisory Board	4.2yrs	no data	no data
Min Xu	Director	2.9yrs	no data	no data
Kejia Li	Supervisor	2.4yrs	no data	no data
Yanbo Sun	Director	1.4yrs	CN¥189.20k	0.0025% CN¥ 34.6k

5.4yrs

Average Tenure

48yo

Average Age

Experienced Board: 688217's board of directors are considered experienced (5.4 years average tenure).

Shanghai Rightongene Biotechnology Management

Management criteria checks 3/4

Key information

Recent management updates

Shanghai Rightongene Biotechnology Co., Ltd., Annual General Meeting, May 07, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.02 in 1Q 2023)

Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shanghai Rightongene Biotechnology Co., Ltd., Annual General Meeting, May 07, 2024

Shanghai Rightongene Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024.

Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on February 28, 2024.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 24%

New minor risk - Dividend sustainability

Third quarter 2023 earnings released: EPS: CN¥0.048 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.44 in 2Q 2022)

Shanghai Rightongene Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 22%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.32 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.28 in 2Q 2021)

First quarter 2022 earnings released: CN¥0.04 loss per share (vs CN¥0.39 profit in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.95 (vs CN¥0.93 in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age